technical analysis points to higher highs, page-162

Johno247 - I firmly believe NEU did the right thing raising as much money as possible when they did.

We are all only too aware that CR windows opportunities can vanish quickly, when markets turn or a sector falls out of favour.

What seems to have gone wrong is AE's investment timeframe. I can't believe that NEU mgmt allocated such a large parcel to AE, unless AE expressed a strong interest in NEU's long term prospects. So one can only speculate that for some reason AE's investment horizon has changed for some or all of their holding.

As to the Bell Porter 12c - 21c valuation. Take a look at the report. This is a 12 month sp target. So they have until Oct 2012 to be proved right or wrong.

As difficult as it is to swallow a drop from 3.4c on 02-Nov to today's 2.2c, that's how it goes with junior biotech investing. They are very announcement driven, and these tend to be months apart, so sp volitily is high.